Moreover, activating the σ1 receptor increases vascular endothelial growth factor (VEGF) and low-density lipoprotein receptor-related protein 1 (LRP-1) expression levels and attenuates the blood–brain barrier (BBB) dysfunction caused by amyloid deposition in AD [48]. Here, LRP1 is linked to amyloidosis.